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Vibrio cholerae causes diarrhea by colonizing the human small bowel and intoxicating epithelial cells.
Colonization is a required step in pathogenesis, and strains defective for colonization are significantly atten-
uated. The best-characterized V. cholerae colonization factor is the toxin-coregulated pilus (TCP). It has been
demonstrated that TCP is required for V. cholerae colonization in both humans and mice. TCP enhances
bacterial interactions that allow microcolony formation and thereby promotes survival in the intestine. We
have recently discovered that the TCP biogenesis apparatus also serves as a secretion system, mediating the
terminal step in the extracellular secretion pathway of TcpF. TcpF was identified in classical isolates of V.
cholerae O1 as a soluble factor essential for colonization in the infant mouse cholera model. In the present
study, we expanded our analysis of TcpF to include the O1 El Tor and O139 serogroups and investigated how
TCP and TcpF act together to mediate colonization. Additionally, we demonstrated that antibodies generated
against TcpF are protective against experimental V. cholerae infection in the infant mouse cholera model. This
observation, coupled with the fact that TcpF is a potent mediator of colonization, suggests that TcpF should
be considered as a component of a polyvalent cholera vaccine formulation.
Vibrio cholerae is a gram-negative bacillus that causes the
acute diarrheal disease cholera (for a review see reference 22).
Although there are over 200 serogroups of V. cholerae based
on the surface polysaccharide O antigen and several of these
serogroups may cause sporadic, minor cases of cholera, epi-
demic V. cholerae isolates are represented by only two sero-
groups, serogroups O1 and O139. The O1 serogroup is further
separated into two biotypes, classical and El Tor, based on
physiologic variability. The easily demonstrable physiological
differences between El Tor and classical isolates include hem-
agglutination of chicken erythrocytes, polymyxin B resistance,
and hemolysis of sheep erythrocytes; all of these properties are
characteristic of the El Tor biotype (22).
Cholera is transmitted via the oral-fecal route, and ingestion
of a significant V. cholerae inoculum is required to produce the
clinical syndrome (5). After a short incubation period, patients
with cholera present with voluminous, watery diarrhea. In the
absence of rehydration therapy, hypovolemic shock and death
can ensue (4). These clinical manifestations are the direct
result of intoxication of intestinal epithelial cells by cholera
toxin (CT). CT is delivered to epithelial cells by V. cholerae that
has successfully colonized the upper small intestine; coloniza-
tion is therefore a required step in V. cholerae pathogenesis.
The molecular mechanism by which CT causes diarrhea is
well understood. CT enters the endocytic pathway of intestinal
epithelial cells and through a cascade of intermediates consti-
tutively alters the permeability of these cells to ions and water
(6, 20, 21, 47). Increased fluid and electrolyte secretion cou-
pled with decreased absorption leads to abnormal luminal ac-
cumulation of fluid. Much less is known about how the proteins
and other factors involved in intestinal colonization mediate
interactions with intestinal epithelial cells and among bacteria
to promote a productive infection. One possible way to con-
ceptualize intestinal colonization is by comparison with a po-
tentially similar bacterial process, biofilm formation. This is a
general mechanism by which bacteria colonize surfaces and
can be thought of as a stepwise process composed of at least
three distinct events: (i) surface attachment, (ii) microcolony
formation, and (iii) assembly of higher-order structures (mac-
rocolonies or biofilms) (10, 50). Based on this model, it would
be expected that mutations in genes encoding proteins in-
volved in each of these steps would cause deficiencies that
prevent progression of the biofilm formation process. This
model is supported by the fact that mutations resulting in
deficiencies in most of these steps have been described in
Pseudomonas aeruginosa, for which colonization of plastic sur-
faces was used as a screening tool to identify such mutants
(32–34). Additionally, more recent work has established that V.
cholerae biofilm formation on plastic surfaces is a process that
requires particular gene products to accomplish various steps,
all of which are required for the formation and maintenance of
biofilms (3, 50, 51).
Extending this concept to include intestinal colonization by
V. cholerae, proteins believed to be involved in mediating the
first two steps have been identified and characterized to vary-
ing degrees. For example, it has been suggested that OmpU, a
major V. cholerae outer membrane protein, binds to fibronectin
in the cellular matrix of eukaryotic cells, placing it among the
mediators of the first step. Antibodies against OmpU were
shown to block colonization in passive immunization experi-
ments (37). In addition, we recently identified an outer mem-
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brane protein (GbpA) that appears to mediate direct attach-
ment to epithelial cells by binding to surface-exposed sugars
(Kirn et al., submitted for publication). Deletion of the gene
encoding this protein results in a significant in vivo coloniza-
tion defect.
While analysis of the proteins involved in the first step of
colonization has been limited, the best-characterized V. chol-
erae colonization factor is the toxin-coregulated pilus (TCP),
which is a representative factor involved in mediating the sec-
ond step of colonization (bacterium-bacterium interactions
leading to microcolony formation). TCP is a type 4 pilus that
has long been recognized as a protein that is structurally re-
lated to the bundle-forming pilus of enteropathogenic Esche-
richia coli (11). More recently, it has become clear that based
on the arrangement of the genes encoding the TCP biogenesis
apparatus, TCP is also closely related to the type 4 pili elabo-
rated by enterotoxigenic E. coli (ETEC) and Citrobacter roden-
tium (CFA/III and CFC, respectively) (31, 42). The elabora-
tion of TCP confers several important properties upon V.
cholerae in vitro and in vivo. Since TCP is the high-affinity
receptor for the CTX phage, TCP bacteria are efficiently
transduced by the CTX derivative CTX-Kn, while TCP
strains are poorly transduced (49). Furthermore, TCP V.
cholerae strains are protected from complement-mediated cytol-
ysis, while TCP strains are sensitive (8, 24). Perhaps most
importantly, it has been shown that TCP is required for colo-
nization in human volunteers and in the infant mouse cholera
model for all epidemic serogroups and biotypes of V. cholerae
(18, 41, 44, 45). While many type 4 pili function by mediating
a direct interaction between bacteria and epithelial cells, TCP
appears to enhance bacterial interactions, thereby promoting
the assembly of intestinal microcolonies (24). Presumably, the
formation of intestinal microcolonies protects the bacteria
from biological, chemical, or physical threats, allowing them to
persist and cause disease. As might be expected, blocking the
function of the pilin subunit (TcpA) with antibodies signifi-
cantly reduces the ability of V. cholerae to colonize and is
protective (38, 52).
V. cholerae mutants defective for the third intestinal coloni-
zation step have not been described yet, suggesting that this
step is not required for colonization or that it is impossible to
evaluate this phenotype in vitro. However, we recently dem-
onstrated that TcpF, a soluble protein secreted via the TCP
biogenesis apparatus, plays an important role in colonization
(23). Mutants lacking the ability to produce TcpF are severely
defective for colonization in the infant mouse cholera model,
while they essentially retain all of the in vitro properties asso-
ciated with the elaboration of a functional TCP. Based on
these observations, it is possible that TcpF may be the first
representative of a class of proteins required for the third step
of colonization. As mentioned above, operons encoding the
proteins involved in the biogenesis of the ETEC CFA/III and
C. rodentium CFC pili have recently been characterized. Inter-
estingly, alignment of the genes encoding pilus biogenesis func-
tions in these two organisms with the tcp operon revealed that
in each case a nonhomologous gene occupies the same position
within the operon as tcpF. In both cases, the predicted proteins
have no known function and exhibit limited homology to well-
characterized proteins. It is intriguing to consider that these
proteins may play roles in ETEC and Citrobacter pathogenesis
analogous to the role of TcpF in V. cholerae.
In the present study, we compared the phenotypes of mu-
tants defective for TCP and mutants defective for TcpF with
respect to intestinal clearance, in vitro microcolony formation,
and epithelial cell attachment. Additionally, since all previ-
ously reported experiments designed to evaluate the secretion
of TcpF were conducted with the classical O1 strain of V.
cholerae, we expanded our analysis of TcpF to include El Tor
O1 and O139 serotypes. Finally, we demonstrated that anti-
bodies directed against TcpF are protective against experimen-
tal cholera infection in the infant mouse cholera model.
MATERIALS AND METHODS
Bacterial strains and plasmids. Bacteria were grown either in Luria-Bertani
(LB) liquid broth at 37°C for 16 h (standard conditions), in LB broth adjusted to
a starting pH of 6.5 at 30°C for 16 h (classical O1 TCP-inducing conditions), or
in AKI broth (O139 and El Tor O1 TCP-inducing conditions) (19). V. cholerae
strains O395, 569B, and N16961 were obtained from laboratory stocks, and strain
CVD112 was obtained from the Center for Vaccine Development at the Uni-
versity of Maryland (40).
Sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE)
and Western blotting. Each strain was grown under the appropriate TCP-induc-
ing conditions, and culture supernatants were harvested by centrifugation for 5
min at 10,000  g. Each pellet was resuspended in phosphate-buffered saline
(PBS) and mixed with an equal volume of 2 loading buffer. Supernatants were
then filtered through a 0.2-m syringe barrel filter and mixed with an equal
volume of 2 protein loading buffer. Proteins from culture supernatants and
whole-cell extracts were separated on 12.5% polyacrylamide gels containing
SDS. Total-protein determinations were made using the bicinchoninic acid pro-
tein assay (Pierce), and culture supernatant or pellet fractions were diluted
appropriately. For immunodetection, proteins were transferred to nitrocellulose
at 4°C in transfer buffer (25 mM Tris, 192 mM glycine, 20% methanol; pH 8.3)
using a wet transfer apparatus (48). TcpF was detected using polyclonal anti-
TcpF antiserum generated as previously described (23).
CTX-Kn transduction assay. CTX-Kn-containing supernatants were gen-
erated by growing strain CL101 under standard conditions and filtering the
culture supernatant through a 0.2-m syringe filter (26). Transductions were
performed as previously described (49). Briefly, each strain to be tested was
grown under TCP-inducing conditions and mixed with an equal volume of su-
pernatant containing CTX-Kn. After 30 min of incubation at room tempera-
ture, appropriate dilutions were prepared, and the bacteria were plated on solid
medium containing kanamycin. The transduction frequency was calculated by
dividing the number of Kanr colonies recovered by the number of input CFU. All
transductions were performed on the same day with a single phage stock.
LD50 and competitive index analysis. The 50% lethal dose (LD50) of each
strain was assessed by orally inoculating groups of four 5- to 7-day-old mice with
dilutions of bacteria grown under TCP-inducing conditions. The inocula tested
were 10-fold dilutions containing from 5  108 to 5  105 bacteria per dose.
When antibodies were evaluated for the ability to provide protection, an equal
volume of antiserum was mixed with a bacterial suspension just before the mice
were inoculated. The LD50 was based on the extrapolated dose that resulted in
a mean survival rate of 50% after 48 h.
For the in vivo competitive index determinations, strains to be tested were
grown under TCP-inducing conditions and then mixed with equal numbers of the
isogenic lacZ O395 derivative CG842. Five- to 7-day-old CD-1 mice from mixed
litters were orally inoculated with 50 l of a 1 102 dilution of the mixture and
incubated at 30°C for 24 h. The bacteria were then recovered by homogenizing
harvested intestines with a Tissue Tearor in 4 ml of 10% glycerol in LB broth.
The homogenate was appropriately diluted and plated on solid medium contain-
ing streptomycin and 5-bromo-4-chloro-3-indolyl--D-galactopyranoside (X-
Gal). The competitive index was calculated by comparing the ratio of test strain
bacteria recovered from the intestine to the test strain input with the input/
output ratio of CG842. The values plotted were the competitive index for each
mouse along with the average.
In vitro competitive index values were obtained by inoculating 2 ml of LB
liquid medium with equal numbers of the test strain and CG842, growing the
organisms overnight at 37°C, and plating dilutions on solid medium containing
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streptomycin and X-Gal. The change in the ratio of the test strain to CG842 was
then determined.
Serum resistance assay. The serum resistance assay was performed as previ-
ously described (8). Briefly, each strain was grown for 12 h under TCP-inducing
conditions, pelleted in a microcentrifuge, and resuspended in PBS. The cells
were then diluted 1:100 in PBS, and reconstituted lyophilized guinea pig com-
plement was added to a final concentration of 20%. This mixture was divided into
multiple 500-l aliquots, and either anti-O395 antibody at a final concentration
of 1:2,500 or PBS was added. The samples were incubated at 37°C with agitation
for 45 min and then diluted appropriately and plated on solid medium. Serum
resistance was expressed as the number of bacteria recovered after treatment
with antiserum divided by the input number of CFU.
Mixed microcolony assay. Briefly, unmarked wild-type strains together with
mutants bearing pGreenTIR were inoculated into liquid culture media and
grown overnight under TCP-inducing conditions. The presence of fluorescent
bacteria in the resulting bacterial aggregates was scored by confocal fluorescence
microscopy using an overlay of the output from the fluorescein isothiocyanate
channel with the differential interference contrast image.
Cell culture and bacterial attachment assay. HT-29 cells were grown in Dul-
becco modified Eagle medium supplemented with 10% fetal bovine serum and
1 Pen-Strep (Gibco) under 5% CO2 (1). Confluent monolayers were infected
with 1 ml of a bacterial suspension containing 106 bacteria/ml and incubated at
37°C. Bacteria and epithelial cells were imaged by confocal microscopy, and
differential interference contrast images were overlaid with images obtained on
the green fluorescent protein (GFP) channel after 4 h. For quantitation of
attached bacteria, the monolayers and attached bacteria were washed three times
with PBS and then incubated for 30 min in a 1% Triton X-100 solution. The
resulting bacterial suspensions were appropriately diluted and plated on LB
medium plates.
In an effort to ensure that each bacterial colony truly represented a single
bacterium and not a cluster of bacteria (microcolony), a simple control experi-
ment was performed. Briefly, the LacZ wild-type V. cholerae isolate O395 was
mixed at a 1:1 ratio with a LacZ derivative of O395, grown overnight, and then
incubated with epithelial cells as described above. Following lysis of the epithelial
cells, appropriate dilutions of the resulting bacterial suspension were plated on
LB medium plates containing X-Gal. After overnight incubation, an equal mix-
ture of blue and white colonies was observed on the plates, and no mixed
colonies were observed. Ten blue colonies and 10 white colonies were then
restreaked on LB medium plates containing X-Gal and again incubated over-
night. Confirming the hypothesis that each colony represented a single bacte-
rium, each blue colony gave rise to only blue colonies and each white colony gave
rise to only white colonies.
RESULTS
TcpF is secreted by all epidemic types of V. cholerae. We
previously demonstrated that TcpF is secreted at a level similar
to the level of CT secreted by the classical O1 V. cholerae strain
O395 (23). In an effort to determine the ultimate localization
of this secreted protein in vitro, proteins from whole-cell ex-
tracts and culture supernatants were separated by SDS-PAGE,
transferred to nitrocellulose, and then probed with antibodies
directed against TcpF. As shown in Fig. 1, although the total
amount of whole-cell protein loaded on the polyacrylamide gel
was 50 times greater than the amount of culture supernatant
protein loaded, TcpF was barely detectable in the whole-cell
fraction, while the culture supernatant fraction yielded a pair
of very robust bands. This pattern of hybridization (i.e., two
distinct bands corresponding to TcpF) is consistent with pre-
viously reported results (see below). While this experiment was
not precisely quantitative, it clearly demonstrated that a large
majority of TcpF was secreted into the culture supernatant and
remained there in a soluble form during in vitro growth. Im-
munoblotting these same fractions for TcpA revealed that the
large majority of the TcpA was in the whole-cell fraction,
which served as a control for a bacterial associated protein. A
band for TcpF was not detected in the whole-cell or culture
supernatant fractions from the O395 tcpF mutant, demon-
strating the specificity of the anti-TcpF antiserum for the two
species of TcpF secreted by the wild-type strain.
In addition to the more rigorous assessment of the localiza-
tion of TcpF in classical O1 isolates of V. cholerae, we expanded
our analysis of TcpF secretion to include additional strains
representing all epidemic serotypes. As shown in Fig. 1, TcpF
was detectable in culture supernatants isolated from O395
(O1, classical, Ogawa), 569B (O1, classical, Inaba), N16961
(O1, El Tor), and CVD112 (O139) grown under TCP-inducing
conditions (see Materials and Methods). As previously de-
scribed, TcpF was represented by two distinct bands (33 and 36
kDa) in culture supernatants isolated from O395 (23). Inter-
estingly, 569B produced three bands (30, 32, and 36 kDa) that
were cross-reactive with the anti-TcpF sera. These multiple
bands most likely represented degradation products of TcpF or
otherwise modified forms of TcpF. This hypothesis is sup-
ported by the fact that culture supernatants prepared from the
O395 tcpF mutant were devoid of any proteins that cross-
reacted with this antibody. In the case of N16961 and CVD112,
TcpF was represented by a single band on the Western immu-
noblot. This may have been a result of the fact that, overall,
less TcpF was present and the levels of less abundant bands at
lower molecular weights were below the limits of detection. A
lower level of TcpF expression in these strains is consistent
with what is known about TCP expression (25, 46). Alterna-
tively, it is possible that, unlike classical biotype strains, O139
and O1 El Tor strains do not process or modify TcpF.
FIG. 1. Secretion of TcpF from V. cholerae. (A) Determination of
TcpF and TcpA levels in whole-cell extracts (wc) and culture super-
natants (cs) from V. cholerae O395 (wt) and O395 tcpF (tcpF). The
numbers below the lanes indicate the total amounts of protein loaded
as determined by the bicinchoninic acid protein assay (Pierce). (B) Im-
munoblot analysis of culture supernatants from strains representing
each epidemic serogroup (O1 and O139), the two biotypes of O1, and
the two serotypes of classical O1 V. cholerae. The primary antiserum
was generated using a purified TcpF-GST fusion protein.
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TcpF is required for colonization of the infant mouse intes-
tine. We previously reported that in the case of classical V.
cholerae O1, TcpF is required for colonization in the infant
mouse cholera model (23). We have also demonstrated that
the colonization defect of a tcpF mutant could be rescued by
expression of a TcpF-His fusion protein in trans (S. J. Krebs,
T. J. Kirn, and R. K. Taylor, Abstr. 103rd Gen. Meet. Am Soc.
Microbiol., abstr. B-432, 2003). Because few current clinical
cases of cholera are caused by classical V. cholerae isolates, we
expanded this study to include a more clinically relevant V.
cholerae O1 El Tor isolate (N16961). This strain is also of
interest because it was the strain used in the recently com-
pleted V. cholerae genome sequencing project (17). Addition-
ally, since epidemic O139 isolates are physiologically similar to
El Tor O1 isolates and may have even evolved from such
strains, it is likely that results obtained with El Tor strains can
be used as a reliable indicator of the behavior of O139 strains
(2, 30). We generated an in-frame tcpF deletion in the N16961
background to use for in vivo colonization assays. As shown in
Fig. 2, while the wild-type strain N16961 was able to colonize
as well as an isogenic N16961 lacZ mutant, a tcpF mutant
was significantly defective for colonization compared to the
wild-type strain. This was reflected by a competitive index that
was found to be more than 1,000-fold less than that of the
parental strain. As also shown in Fig. 2, this defect was similar
to what was observed for the tcpF mutation in the classical O1
background (O395) when it competed against the isogenic
parental strain. As expected, the mutant and wild-type strains
competed with a ratio of one in vitro (data not shown). This
result demonstrated that TcpF is required in colonization of
the infant mouse intestine by both biotypes of V. cholerae O1,
and this result may be inferred to extend to the O139 sero-
group.
TcpF and TCP are both required for efficient colonization.
We showed previously that TcpF secretion is dependent upon
assembly of the TCP biogenesis apparatus (23). Furthermore,
it has been reported that TCP strains are defective for colo-
nization in infant mice and in humans (18, 44, 45). Since TCP
strains are necessarily deficient for TcpF secretion, it has been
impossible to discern if the phenotype of these mutants is a
result of the loss of the ability to secrete TcpF or the absence
of TCP. To directly determine if TCP and TcpF are both
required for colonization, we assessed the ability of a unique
tcpA point mutant to compete against the parental wild-type
strain in the infant mouse cholera model. As we described
previously, E158L is a single amino acid change in the C
terminus of TcpA that results in elaboration of a morpholog-
ically aberrant pilus (24). While wild-type TCP are bundled,
straight structures, the E158L pilus is wavy, unbundled, and
deficient for some TCP-associated properties, including colo-
nization (Fig. 3). However, the E158L mutant retains the abil-
ity to secrete TcpF (Fig. 3A), making it an excellent strain with
which to separate elaboration of a functional TCP from TcpF
secretion. As shown in Fig. 3C, the E158L mutant was nearly
as defective for colonization as the tcpA mutant (which was
TCP and did not secrete TcpF). This result demonstrates that
TCP and TcpF must both be expressed by the same bacterium
for efficient colonization of the infant mouse intestine. Inter-
estingly, loss of either of these factors reduced colonization by
several logs (in most cases no mutant bacteria were recovered
from the mice), suggesting a cooperative or synergistic func-
tion for TCP and TcpF in colonization.
TCP, TcpF, and TCP TcpF mutants are all cleared
from the infant mouse intestine with similar kinetics. Since
TCP and TcpF were found to be required for colonization to
similar extents, we wanted to determine if we could discern a
difference in the kinetics of clearance of TCP, TcpF, and
TCP TcpF mutants from the mouse intestine. As shown in
Fig. 4, the number of wild-type V. cholerae cells in the intestine
initially declined and then remained nearly constant for the
next 35 h (Fig. 4). In contrast, mutants lacking functional TCP
(E158L), TcpF (tcpF), or both factors (tcpA) were contin-
uously cleared from the intestine over the course of the exper-
iment, and the level approached or reached zero at 35 h.
Importantly, no obvious difference between kinetics was ob-
served for any of the mutants. This result may be interpreted in
two ways. It is possible that TCP and TcpF act in a cooperative
manner during infection and that they both are required at the
same step (the second step) during colonization. Alternatively,
the presence of both of these factors may be required to
progress past a certain step (the third step) in the colonization
process that determines whether a stable population of bacte-
ria remains in the bowel.
tcpF mutants are able to form microcolonies in vitro. Our
previous experiments demonstrated that in vitro microcolony
formation correlates with in vivo colonization (24). Specifically,
tcpA mutants incapable of forming mixed microcolonies with
wild-type bacteria were uniformly defective for colonization.
Based on this finding, we tested the tcpF mutant for the
ability to agglutinate together with the wild-type parental
strain. As shown in Fig. 5, when O395/pGreenTIR was grown
together with unlabeled O395, large microcolonies formed that
appeared to be approximately equally composed of the two
FIG. 2. In vivo competition of wild-type and tcpF mutants in the
infant mouse cholera model. tcpF mutations were generated in O1 El
Tor (N16961) and classical (O395) strains and used in competition
assays with the corresponding wild-type parental strains. The compet-
itive index for each mouse (■) and the average for each group (E) are
shown.
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strains. In contrast, the tcpA pGreenTIR mutant failed to
enter the wild-type microcolonies, and just a few individual
fluorescent bacteria were visible at high magnification. The
tcpF mutant had a somewhat intermediate phenotype. Al-
though the microcolonies included nearly equal numbers of
wild-type and tcpF pGreenTIR bacteria, they were consis-
tently not as tightly packed as the wild-type microcolonies, as
indicated most notably by the decreased adherence of bacteria
around the edges of the microcolonies. Although an interme-
diate phenotype was evident, large microcolonies were formed.
If TcpF enhances colonization by mediating increased bacte-
rial interactions, as TCP does, then the result of a loss of TcpF
in vitro is quite dampened compared to the tcpF phenotype in
vivo. Perhaps a small defect in vitro translates to a large defect
in bacterial interactions in vivo. An alternative explanation is
that TcpF mediates its effects through an entirely different
pathway in vivo.
In an effort to support or refute the role of TcpF in micro-
colony formation in vivo, we assessed the ability of the tcpF
mutant to form microcolonies in an in vitro colonization assay.
Human colonic epithelial cells (HT-29) were infected with the
wild-type, tcpF, or tcpA strain and incubated for 4 h. After
4 h, adherent bacteria were observed by fluorescence micros-
copy. As shown in Fig. 6, the wild-type and tcpF strains
formed large, multicellular microcolonies after 4 h, while the
tcpA mutant was capable of attaching but displayed a reduced
ability to form microcolonies. In order to determine if TcpF
plays a role in epithelial cell attachment, the number of at-
tached bacteria was also determined (Fig. 6). Although the
results of this experiment suggested a reduction in attachment
for the tcpA mutant, the standard deviations overlapped and
no significant difference (P  0.05) in attachment was noted
for either of the mutants when they were compared to each
other or the wild type. These results support our previous
observation that TCP is chiefly involved in mediating interbac-
terial interactions and are consistent with other data showing
that TCP increases attachment to HT-29 cells by only a small
amount (1). Furthermore, these results separate the functions
of TCP and TcpF, suggesting that they act at different steps in
the pathway in order to have a considerable effect on coloni-
FIG. 3. TcpF secretion and TCP biogenesis in the E158L tcpA point mutant. (A) Culture supernatants isolated from wild-type, tcpF, and
E158L strains were analyzed for TcpF secretion by SDS-PAGE and immunoblotting with anti-TcpF antiserum. (B) Transmission electron
micrograph showing TCP elaborated by wild-type V. cholerae (wt) and the nonfunctional, morphologically aberrant pili elaborated by the E158L
mutant. (C) Relevant in vitro and in vivo features of wild-type, tcpA, E158L, and tcpF strains. The presence of stable pilin, pilus features,
autoagglutination (AA), serum resistance, CTX phage transduction efficiency (CTX Tx), and competitive indices (CI) were determined as
previously described (24).
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zation. Specifically, while neither of these factors appeared to
be required for initial attachment in our in vitro assay, TCP
was required for microcolony formation, while TcpF seemed to
play a minor role in this step. Overall, these results support a
multistep model for colonization, in which TcpF functions af-
ter TCP to enhance microcolony formation or mediate other
effects which are ultimately required for intestinal coloniza-
tion.
Antibodies directed against TcpF are protective in the in-
fant mouse cholera model. Since TcpF plays such a critical role
in colonization by all epidemic strains, we wanted to determine
if it was a reasonable target for incorporation into a multiva-
lent vaccine formulation. We therefore investigated if blocking
the TcpF function could protect infant mice inoculated with
wild-type bacteria from disease. As shown in Fig. 7, coinocu-
lation of wild-type bacteria with sera collected from rabbits
immunized with a TcpF-glutathione S-transferase (GST) fu-
sion protein increased the LD50 approximately 100-fold com-
pared to preimmune serum. This reduction in virulence was
FIG. 4. Kinetics of bacterial clearance from the infant mouse in-
testine. (Top panel) Wild-type, tcpA, or tcpF bacteria were individ-
ually inoculated into infant mice, and the number of bacteria coloniz-
ing the small bowel was determined at various times. Each point
represents the average of two mice. (Bottom panel) Wild-type, E158L,
and tcpF samples were each mixed with an equal volume of wild-type
bacteria (which were lacZ mutants) prior to inoculation, and the
numbers of LacZ colonies remaining in the intestine at various times
were determined. Each point represents the average of two mice.
FIG. 5. Wild-type in vitro microcolony formation compared to mi-
crocolony formation by the tcpA and tcpF mutants. Wild-type V.
cholerae was grown under TCP-inducing conditions along with wild-
type, tcpA, and tcpF V. cholerae strains bearing a plasmid encoding
GFP. The images of the mixed microcolonies include fluorescein iso-
thiocyanate channel signals (green) overlaying differential interference
contrast signals (grey).
FIG. 6. Attachment of V. cholerae mutants to HT-29 epithelial
cells. Wild-type, tcpA, and tcpF strains bearing a plasmid encoding
GFP were inoculated into tissue culture wells containing a confluent
layer of HT-29 human colonic epithelial cells. After growth for 4 h,
representative photographs were taken, and the number of attached
bacteria was determined by appropriately diluting and plating bacteria.
The numbers below the micrographs are the ratios of the number of
bacteria attached to epithelial cells to the input numbers (means 	
standard deviations).
FIG. 7. Protection of infant mice from experimental cholera infec-
tion by passive immunization with anti-TcpF antiserum. Dilutions of
overnight cultures of wild-type V. cholerae (wt) were mixed with either
preimmune or hyperimmune sera from rabbits immunized with puri-
fied TcpF-GST. The bars indicate the LD50 at 48 h.
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intermediate between complete abrogation of the TcpF func-
tion (tcpF mutant) and the wild-type phenotype. This level of
protection is similar to that seen for antibodies directed against
TcpA (38). Since TcpF is a secreted protein, it is likely that the
mechanism by which the hyperimmune sera provide protection
involves blocking of colonization by direct binding to TcpF in
the intestinal lumen. This hypothesis is supported by the fact
that the TcpF antisera failed to agglutinate wild-type bacteria
in vitro, and, despite numerous attempts, we have been unable
to demonstrate binding of the TcpF antisera to the bacterial
surface or to TCP using immunoelectron microscopy (data not
shown).
DISCUSSION
Colonization of the small bowel by V. cholerae may be con-
ceptualized as a series of discrete steps, much like biofilm
formation on abiotic or biotic surfaces (10, 50). We propose
that colonization likely begins with surface attachment, pro-
ceeds to microcolony formation, and ultimately concludes with
the production of the large, multicellular bacterial communi-
ties characteristic of biofilms (Fig. 8). Such aggregations of V.
cholerae have previously been demonstrated to form in the
intestines of experimentally infected mice and in resected spec-
imens of human small bowel (24, 53). V. cholerae undoubtedly
employs the functions of a variety of proteins to efficiently
colonize the human small intestine, and it is likely that each of
the steps requires a number of proteins or protein complexes.
In the current investigation we extended our studies of one
protein, TcpF, which has a potent effect on this process. tcpF
mutants are capable of adhering to intestinal epithelial cells
and producing microcolonies (Fig. 5 and 6), yet they are se-
verely attenuated for colonization of the infant mouse intestine
(Fig. 2). While we previously showed that V. cholerae mutants
lacking the ability to form microcolonies in vitro were uni-
formly defective for colonization, the work presented here
separated these two phenotypes (24).
The phenotype of the tcpF mutant suggests that the TcpF
protein may exert its effect at the level of formation of higher-
order bacterial complexes. Alternatively, it is possible that our
in vitro microcolony or attachment assays were not sensitive
enough to detect small defects in bacterial interactions that
translate into severe defects in vivo. This is suggested by the
results shown in Fig. 5, which revealed a slight defect in agglu-
tination when mutants were mixed with wild-type bacteria.
FIG. 8. Proposed model for V. cholerae intestinal colonization. We propose the following three-step model for colonization: (i) initial
attachment (step 1), (ii) microcolony formation (step 2), and (iii) macrocolony formation and maintenance (step 3). Factors that may be involved
in each of these steps are listed. Relevant micrographs show GFP-expressing V. cholerae (green) colonizing HT-29 cells (grey) in vitro after 1 and
4 h of incubation; for step 1 the magnification is400, and for step 2 the magnification is1,000. The micrograph for step 3 shows an infant mouse
intestine (blue) colonized by GFP-expressing V. cholerae (green) 16 h after oral inoculation (magnification, 200).
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Additionally, previously we showed that the tcpF mutant was
slightly defective for in vitro autoagglutination by employing a
quantitative assay for this phenotype and that expression of
TcpF in trans complemented this defect (23). Since the in vitro
colonization assay that we employed to investigate the first two
steps of the colonization process is not suitable for analysis of
the formation of macrocolonies, we had to rely on the results
of the in vivo experiments to investigate these later events. As
shown in Fig. 4, the TcpF strain was cleared from the infant
mouse intestine with the same kinetics as a TCP strain, re-
gardless of whether the mutant was mixed with a wild-type
strain. This is notable because it suggests that no real “com-
petition” occurred in these experiments but that the mutant
which was unable to colonize simply transited the infant mouse
intestine quite rapidly. Our in vitro experiments predicted that
the TcpF strain is capable of forming microcolonies in vivo,
while the TCP mutant is not. Taken together, these results
may be interpreted to demonstrate that both of these mutants
are blocked at the same step (microcolony formation) or that
the TCP mutant is defective for microcolony formation and
the TcpF mutant is defective at a later step, yet both of these
deficiencies result in an inability to establish a productive in-
fection, leading to rapid intestinal clearance. In other words,
the ability to form microcolonies in vivo does not protect the
bacteria from rapid clearance, while the formation of higher-
order structures does. Furthermore, it is possible that these
two steps (namely, microcolony formation and the formation
of higher-order structures) are mechanistically separate events
(the former mediated by TCP and the latter mediated by
TcpF), yet temporally very closely related.
Interestingly, when wild-type V. cholerae was mixed with the
tcpF mutant and both strains were orally fed to infant mice, the
wild-type strain was unable to rescue the tcpF phenotype in
trans. This result was unexpected because our previous exper-
iments and the data shown in Fig. 1 demonstrated that TcpF is
a soluble factor and therefore would be expected to function in
trans. Several explanations for this observation are equally
plausible. It is possible that TcpF interacts with TCP or the
bacterial membrane in vivo, yet is recovered as a soluble pro-
tein in vitro. A second possibility is that TcpF may exert its
effect immediately upon secretion, in close proximity to the
bacteria that secrete it. This is consistent with a model in which
TCP-mediated interactions bring bacteria into close proximity
with one another and then TcpF, secreted by the bacteria in a
given microcolony, strengthens or stabilizes the interbacterial
interaction.
Regardless of the exact mechanism by which TcpF enhances
colonization, blocking its function could certainly be a reason-
able approach to preventing disease in humans. Recent ap-
proaches to cholera vaccine design have largely focused on the
production of live attenuated oral formulations. Several live
vaccines have been developed, including CVD103-HgR (clas-
sical, Inaba), CVD 111 (El Tor, Ogawa), combined CVD 103-
HgR, CVD 111, Peru-15 (El Tor, Inaba), Bengal-15 (O139),
and V. cholerae 638 (El Tor, Ogawa) (9, 27, 43). The results of
field trials with some of these formulations were quite favor-
able, although protection was often highly variable and re-
quired more than one dose (35, 36). These results may have
been in part related to differential expression of antigens that
engender protective immunity. Several studies have docu-
mented the efficacy of antibodies directed against V. cholerae
subunits (TcpA and lipopolysaccharide) for protection from
disease in the infant mouse cholera model (7, 28, 38, 39, 52).
Subunit vaccines may prove to be superior to whole-cell live
vaccines since the appropriate antigens can reliably be intro-
duced into each individual at the appropriate dose. In addition,
enhanced immunologic responses can be induced by incorpo-
rating appropriate biological response mediators into the vac-
cine formulation (29). Based on the results presented here, we
propose that TcpF may be a reasonable antigen to include in a
polyvalent subunit vaccine formulation. Combined with anti-
lipopolysaccharide and anti-TCP responses, antibodies di-
rected against TcpF may potently inhibit colonization in the
human intestine, thereby preventing disease (7, 52). Further-
more, if antigens representing proteins involved in each step of
the colonization process are combined into a vaccine formu-
lation, a higher degree of protection may be provided than that
obtained with a single subunit or with multiple subunits, each
of which is a portion of proteins involved in the same step of
colonization. This concept is well illustrated by the evolution of
the pertussis vaccine in the United States. Pertussis is a severe,
acute respiratory disease caused by the gram-negative bacte-
rium Bordetella pertussis. Much like cholera, pertussis is pri-
marily a toxin-mediated disease. Following colonization of the
respiratory epithelium, B. pertussis produces toxins that para-
lyze the cilia and cause inflammation in the respiratory tract,
potentially causing pneumonia. A whole-cell pertussis vaccine
was developed in the mid-1930s and was combined into the
diphtheria-tetanus-pertussis combination vaccine in the mid-
1940s. This combination vaccine was reasonably efficacious
(70% to 90%), with protection lasting 5 to 10 years. Local
adverse reactions were common with this vaccine, and severe
systemic events occurred less frequently yet were common
enough to prompt interest in the development of a safer vac-
cine. Based on advances in our understanding of the molecular
mechanisms of B. pertussis pathogenesis, several acellular, mul-
tisubunit vaccines were developed. The components present in
these vaccines include adhesive proteins involved in coloniza-
tion (pertactin, filamentous hemagglutinin, fimbria types 2 and
3), and pertussis toxoid. These acellular vaccines were intro-
duced into clinical practice in the United States in 1991 as the
fourth and fifth doses of a five-dose series and were approved
for use in the primary series in 1996 as part of the diphtheria-
tetanus-acellular pertussis combination vaccine. In addition to
reducing the number of adverse events associated with pertus-
sis vaccination, these formulations also proved to be at least as
protective as their whole-cell predecessor (7, 12–15, 28). Re-
cent studies have demonstrated that humans are capable of
mounting an immune response to TcpF during V. cholerae
infection, further validating the hypothesis that TcpF is a viable
option for inclusion in a multisubunit cholera vaccine (16).
Obviously, further work is required to more completely un-
derstand TcpF function in vivo and to identify specific regions
within TcpF that elicit protective immunity. We are currently
using genetic and immunological approaches to further define
the function of TcpF in the colonization process and to identify
discrete regions of this protein that are important for protec-
tion.
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